BR112015008418A2 - uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae - Google Patents

uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae

Info

Publication number
BR112015008418A2
BR112015008418A2 BR112015008418A BR112015008418A BR112015008418A2 BR 112015008418 A2 BR112015008418 A2 BR 112015008418A2 BR 112015008418 A BR112015008418 A BR 112015008418A BR 112015008418 A BR112015008418 A BR 112015008418A BR 112015008418 A2 BR112015008418 A2 BR 112015008418A2
Authority
BR
Brazil
Prior art keywords
streptococcus pneumoniae
immunogenic composition
targeted
individual
methods
Prior art date
Application number
BR112015008418A
Other languages
English (en)
Inventor
Verlant Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218660.7A external-priority patent/GB201218660D0/en
Priority claimed from US13/827,203 external-priority patent/US20140105927A1/en
Priority claimed from US13/826,932 external-priority patent/US20140193451A1/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112015008418A2 publication Critical patent/BR112015008418A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

1 / 1 resumo “uso de uma composiã‡ãƒo imunogãšnica, composiã‡ãƒo imunogãšnica, e, mã‰todos para intensificar atividade opsã”nica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivãduo e para imunizar um hospedeiro humano contra doenã‡as causadas por infecã‡ãƒo por streptococcus pneumoniae” a presente invenã§ã£o refere-se a uma composiã§ã£o imunogãªnica compreendendo (i) pelo menos uma proteã­na de streptococcus pneumoniae; (ii) um sacarã­deo capsular de streptococcus pneumoniae derivado de uma cepa de um sorotipo alvejado de streptococcus pneumoniae; para uso na intensificaã§ã£o de atividade opsã´nica mediada por anticorpo contra o sorotipo alvejado de streptococcus pneumoniae.
BR112015008418A 2012-10-17 2013-10-15 uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae BR112015008418A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261714956P 2012-10-17 2012-10-17
US201261714942P 2012-10-17 2012-10-17
GBGB1218660.7A GB201218660D0 (en) 2012-10-17 2012-10-17 Immunogenic composition
US13/827,203 US20140105927A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/826,696 US9561268B2 (en) 2012-10-17 2013-03-14 Immunogenic composition
US13/826,932 US20140193451A1 (en) 2012-10-17 2013-03-14 Immunogenic composition
PCT/EP2013/071483 WO2014060389A2 (en) 2012-10-17 2013-10-15 Immunogenic composition

Publications (1)

Publication Number Publication Date
BR112015008418A2 true BR112015008418A2 (pt) 2017-07-04

Family

ID=53008966

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112015008417A BR112015008417A8 (pt) 2012-10-17 2013-10-15 composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015008419-2A BR112015008419B1 (pt) 2012-10-17 2013-10-15 Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
BR112015008418A BR112015008418A2 (pt) 2012-10-17 2013-10-15 uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR112015008417A BR112015008417A8 (pt) 2012-10-17 2013-10-15 composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015008419-2A BR112015008419B1 (pt) 2012-10-17 2013-10-15 Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina

Country Status (13)

Country Link
EP (3) EP2908855B1 (pt)
JP (3) JP6236086B2 (pt)
KR (2) KR20150072444A (pt)
CN (2) CN104853768B (pt)
AU (2) AU2013333975A1 (pt)
BR (3) BR112015008417A8 (pt)
CA (3) CA2888300A1 (pt)
EA (2) EA201590490A1 (pt)
ES (1) ES2640320T3 (pt)
IL (2) IL238053A0 (pt)
MX (2) MX2015005002A (pt)
SG (2) SG11201502634TA (pt)
WO (3) WO2014060389A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104306965B (zh) * 2014-10-31 2017-05-10 康希诺生物股份公司 预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法
CN108367063A (zh) * 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
CN106432512B (zh) * 2016-09-30 2022-03-01 康希诺生物股份公司 一种增强多糖抗原免疫原性蛋白载体及其制备方法与应用
JP7446227B2 (ja) * 2018-01-19 2024-03-08 オービーアイ ファーマ，インコーポレイテッド Ｃｒｍ１９７タンパク質の発現方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203917B1 (pl) * 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PE20020126A1 (es) * 2000-06-29 2002-04-27 Smithkline Beecham Biolog Composicion de vacuna
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2192127B1 (en) * 2003-12-23 2012-05-09 Nationwide Children's Hospital, Inc. Haemophilus influenzae type IV Pili
EP2298794A3 (en) * 2005-07-08 2011-04-06 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
BRPI0707154B8 (pt) * 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
EA200901578A1 (ru) * 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
MX2011006922A (es) * 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
AU2010290931B2 (en) * 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
CA2783955A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions
US9944680B2 (en) * 2010-12-03 2018-04-17 Sandfi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
AR086405A1 (es) * 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa Vacuna de streptococcus pneumoniae

Also Published As

Publication number Publication date
JP2015536312A (ja) 2015-12-21
EA201590490A1 (ru) 2015-10-30
KR20150058571A (ko) 2015-05-28
AU2013331781A8 (en) 2015-05-14
MX365842B (es) 2019-06-17
WO2014060385A1 (en) 2014-04-24
JP6412500B2 (ja) 2018-10-24
KR20150072444A (ko) 2015-06-29
CA2888310C (en) 2021-07-06
BR112015008417A2 (pt) 2017-07-04
WO2014060383A1 (en) 2014-04-24
WO2014060389A3 (en) 2014-09-12
EP2908854A2 (en) 2015-08-26
AU2013333975A1 (en) 2015-05-07
BR112015008417A8 (pt) 2019-09-10
CN104853768B (zh) 2019-04-19
MX2015004949A (es) 2015-07-06
IL238053A0 (en) 2015-05-31
EA201590491A1 (ru) 2016-01-29
CN104968366B (zh) 2017-12-01
JP2015534962A (ja) 2015-12-07
SG11201502634TA (en) 2015-05-28
CA2888300A1 (en) 2014-04-24
EP2908856A1 (en) 2015-08-26
SG11201502635SA (en) 2015-05-28
CN104853768A (zh) 2015-08-19
CA2888321A1 (en) 2014-04-24
EP2908856B1 (en) 2019-02-20
JP2015534964A (ja) 2015-12-07
ES2640320T3 (es) 2017-11-02
BR112015008419B1 (pt) 2022-11-08
CA2888310A1 (en) 2014-04-24
WO2014060389A2 (en) 2014-04-24
MX2015005002A (es) 2015-07-17
EP2908855B1 (en) 2017-06-28
BR112015008419A2 (pt) 2017-07-04
EP2908855A1 (en) 2015-08-26
IL238079A0 (en) 2015-05-31
BR112015008419A8 (pt) 2019-09-10
CN104968366A (zh) 2015-10-07
AU2013331781A1 (en) 2015-05-07
JP6236086B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
BR112015008418A2 (pt) uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112015005772A2 (pt) método para a intensificação de imunoterapias específicas no tratamento de câncer
BR112015031883A2 (pt) anti-pd-1 anticorpo e o uso dele
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112015030514A2 (pt) Composições e métodos para conjugação de anticorpos ativáveis
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
BRPI0813307B8 (pt) composição imunogênica, vacina, e, processo para fabricar a vacina
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
WO2014107652A3 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
PH12015500480A1 (en) Antibody formulations and uses thereof
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112015004515A2 (pt) composição imunogênica
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]